{{cart_num}}
My CartCAS：149003-01-0
Storage：Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：≥99%
Appearance：White to off-white Solid
Qty：
Size：
| CAS | 149003-01-0 |
| Name | ICRF-187 Hydrochloride |
| Molecular Formula | C11H16N4O4·HCl |
| Molecular Weight | 304.73 |
| Solubility | Soluble in Water/DMSO |
| Purity | ≥99% |
| Appearance | White to off-white Solid |
| Storage | Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| MDL | MFCD00912156 |
| SMILES | C[C@H](N(C1)CC(NC1=O)=O)CN(C2)CC(NC2=O)=O.[xHCl] |
| Target Point | TopoII |
| Passage | DNA Damage/DNA Repair |
| Background | It is an intracellular iron chelator that can reduce the generation of oxygen free radicals and is an inhibitor of topoisomerase II. |
| Biological Activity | Dexrazoxane is a potent metal ion chelator as well as being a catalytic inhibitor of DNA topoisomerase II. [2]Dexrazoxane (ICRF-187) is the only clinically approved cardioprotective agent against anthracycline cardiotoxicity. Its activity has traditionally been attributed to the iron-chelating effects of its metabolite with subsequent protection from oxidative stress. [1] |
| In Vitro | Dexrazoxane may protect cardiomyocytes via its catalytic TOP2 inhibitory activity rather than iron-chelation activity.[1] |
| In Vivo | Triple-treatment with systemic dexrazoxane was superior to single dosage and completely prevented lesions after s.c. daunorubicin and doxorubicin. Low-dose i.l. dexrazoxane was effective in protecting as well.Dexrazoxane is extremely effective and apparently quite specific in protecting against lesions after s.c. doxorubicin and daunorubicin.[2] |
| Animal Experiment | Mice were injected s.c. with daunorubicin or doxorubicin. Systemic N-acetylcysteine，alfa-tocoferol，amifostine，merbarone，aclarubicin，ADR-925，and EDTA were administered i.p. immediately hereafter or as a triple-treatment over six hours. Intralesional(i.l.)adjuvants were injected immediately after and into the same area as the anthracycline. The frequency，duration，and sizes of wounds were observed until complete healing of all wounds.[2] |
| Data Literature Source | [1]. Vavrova A，Jansova H，Mackova E，Machacek M，Haskova P，Tichotova L，Sterba M，Simunek T. Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells. PLoS One. 2013 Oct 7;8(10):e76676. [2]. Langer SW，Sehested M，Jensen PB. Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice. Ann Oncol. 2001 Mar;12(3):405-10. [3]. |
| Unit | Bottle |
| Specification | 10mg 50mg 100mg |
是一种胞内铁螯合剂，能够减少氧自由基 的生成，是topoisomerase II的抑制剂。
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Manual Download
